liothyronine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1585 6893-02-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • liothyronine
  • liothyronine sodium
  • triiodothyronine
  • liothyronin
A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
  • Molecular weight: 650.98
  • Formula: C15H12I3NO4
  • CLOGP: 2.33
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 3
  • TPSA: 92.78
  • ALOGS: -4.52
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mcg O
60 mcg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ

Approvals:

DateAgencyCompanyOrphan
May 8, 1956 FDA KING PHARMS R AND D

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sensitisation 214.79 14.17 53 10881 1529 50592661
Polycystic ovaries 195.68 14.17 54 10880 2430 50591760
Ejection fraction 172.02 14.17 42 10892 1158 50593032
Hypothyroidism 152.99 14.17 94 10840 34031 50560159
Rhinitis allergic 142.79 14.17 55 10879 7145 50587045
Sleep apnoea syndrome 117.92 14.17 70 10864 23798 50570392
Blood test abnormal 115.68 14.17 54 10880 11265 50582925
Carpal tunnel syndrome 111.77 14.17 60 10874 16833 50577357
Sleep disorder due to a general medical condition 103.70 14.17 44 10890 7327 50586863
Burning sensation 89.55 14.17 76 10858 45370 50548820
Nephrectomy 88.71 14.17 23 10911 812 50593378
Fibromyalgia 76.13 14.17 69 10865 44909 50549281
Cardiac disorder 74.84 14.17 67 10867 42912 50551278
Asthma 60.51 14.17 85 10849 89252 50504938
Gastrooesophageal reflux disease 56.69 14.17 76 10858 76352 50517838
Ejection fraction abnormal 55.73 14.17 16 10918 831 50593359
Renal disorder 50.10 14.17 44 10890 27461 50566729
Loss of personal independence in daily activities 47.93 14.17 67 10867 69983 50524207
Therapeutic product effect incomplete 40.95 14.17 72 10862 91443 50502747
Urine chloride decreased 40.54 14.17 8 10926 78 50594112
Suicidal ideation 36.43 14.17 52 10882 55333 50538857
Urine sodium decreased 35.54 14.17 8 10926 153 50594037
Headache 35.46 14.17 208 10726 506327 50087863
Myopathy 33.03 14.17 22 10912 9117 50585073
Weight increased 31.92 14.17 106 10828 201785 50392405
Hyperthyroidism 31.71 14.17 24 10910 12151 50582039
Hypertension 30.85 14.17 108 10826 211095 50383095
Product substitution issue 28.67 14.17 24 10910 14033 50580157
Palpitations 25.16 14.17 60 10874 94446 50499744
Thyroid function test abnormal 22.49 14.17 12 10922 3320 50590870
Feeling abnormal 21.71 14.17 68 10866 125424 50468766
Tri-iodothyronine increased 20.90 14.17 5 10929 126 50594064
Blood thyroid stimulating hormone increased 20.42 14.17 14 10920 6078 50588112
Acute kidney injury 20.39 14.17 12 10922 228046 50366144
Blood thyroid stimulating hormone abnormal 19.57 14.17 7 10927 738 50593452
Nail growth abnormal 18.44 14.17 6 10928 475 50593715
Thyroid cancer 17.43 14.17 11 10923 4158 50590032
Reaction to excipient 16.55 14.17 7 10927 1155 50593035
Systemic lupus erythematosus 16.39 14.17 5 10929 140617 50453573
Drug intolerance 16.34 14.17 14 10920 219090 50375100
Pre-existing condition improved 16.33 14.17 13 10921 7084 50587106
Product quality issue 16.07 14.17 26 10908 30832 50563358
Tri-iodothyronine decreased 15.96 14.17 4 10930 123 50594067
Scar 15.92 14.17 16 10918 11802 50582388
Glossodynia 15.64 14.17 3 10931 115566 50478624
Vascular injury 15.00 14.17 6 10928 859 50593331
Blood thyroid stimulating hormone decreased 14.97 14.17 10 10924 4162 50590028
Maternal exposure during pregnancy 14.86 14.17 8 10926 159770 50434420
Arthropathy 14.55 14.17 8 10926 157898 50436292
Product preparation error 14.54 14.17 10 10924 4362 50589828

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhythm idioventricular 48.88 25.16 9 1519 273 29572726
Secondary hypogonadism 48.75 25.16 9 1519 277 29572722
Thyrotoxic periodic paralysis 45.24 25.16 7 1521 71 29572928
Autoimmune thyroiditis 42.39 25.16 10 1518 1026 29571973
Loose associations 39.23 25.16 6 1522 56 29572943
Performance enhancing product use 38.33 25.16 6 1522 66 29572933
Glucose tolerance decreased 37.77 25.16 6 1522 73 29572926
Diffuse vasculitis 37.70 25.16 6 1522 74 29572925
Sinus arrest 34.22 25.16 9 1519 1438 29571561
Feelings of worthlessness 30.48 25.16 6 1522 261 29572738
Haematocrit increased 28.17 25.16 8 1520 1700 29571299
Hyperthyroidism 28.03 25.16 12 1516 8596 29564403
Pressure of speech 27.25 25.16 6 1522 452 29572547

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sensitisation 229.45 15.60 53 9594 1678 64487407
Polycystic ovaries 223.02 15.60 54 9593 2101 64486984
Ejection fraction 184.50 15.60 42 9605 1244 64487841
Rhinitis allergic 152.54 15.60 54 9593 8024 64481061
Hypothyroidism 143.34 15.60 84 9563 40373 64448712
Carpal tunnel syndrome 133.26 15.60 59 9588 15769 64473316
Blood test abnormal 121.18 15.60 52 9595 12891 64476194
Sleep disorder due to a general medical condition 111.10 15.60 43 9604 8191 64480894
Fibromyalgia 110.51 15.60 68 9579 35663 64453422
Sleep apnoea syndrome 108.44 15.60 63 9584 29769 64459316
Burning sensation 99.19 15.60 72 9575 49592 64439493
Nephrectomy 84.96 15.60 23 9624 1399 64487686
Cardiac disorder 78.98 15.60 66 9581 55750 64433335
Gastrooesophageal reflux disease 72.41 15.60 75 9572 83068 64406017
Asthma 62.37 15.60 74 9573 95151 64393934
Hyperthyroidism 54.66 15.60 34 9613 18145 64470940
Loss of personal independence in daily activities 51.94 15.60 59 9588 72395 64416690
Renal disorder 50.38 15.60 42 9605 35323 64453762
Ejection fraction abnormal 49.16 15.60 15 9632 1398 64487687
Therapeutic product effect incomplete 46.79 15.60 67 9580 103415 64385670
Urine chloride decreased 42.36 15.60 8 9639 91 64488994
Headache 41.84 15.60 173 9474 529294 63959791
Hypertension 37.60 15.60 104 9543 259157 64229928
Secondary hypogonadism 37.18 15.60 9 9638 349 64488736
Thyrotoxic periodic paralysis 35.99 15.60 7 9640 94 64488991
Urine sodium decreased 34.18 15.60 8 9639 268 64488817
Rhythm idioventricular 33.79 15.60 9 9638 514 64488571
Loose associations 32.56 15.60 6 9641 59 64489026
Tri-iodothyronine increased 31.61 15.60 7 9640 182 64488903
Glucose tolerance decreased 31.17 15.60 6 9641 76 64489009
Performance enhancing product use 30.68 15.60 6 9641 83 64489002
Diffuse vasculitis 29.25 15.60 6 9641 107 64488978
Myopathy 27.27 15.60 22 9625 17658 64471427
Insulin-like growth factor increased 27.26 15.60 10 9637 1642 64487443
Suicidal ideation 27.05 15.60 41 9606 66501 64422584
Blood thyroid stimulating hormone decreased 24.33 15.60 13 9634 5217 64483868
Weight increased 23.74 15.60 78 9569 213270 64275815
Feelings of worthlessness 20.55 15.60 6 9641 480 64488605
Autoimmune thyroiditis 19.95 15.60 10 9637 3518 64485567
Blood thyroid stimulating hormone increased 19.74 15.60 13 9634 7641 64481444
Product substitution issue 19.02 15.60 18 9629 17843 64471242
Thrombocytopenia 19.01 15.60 5 9642 223796 64265289
Thyroid function test abnormal 18.79 15.60 9 9638 2870 64486215
Product preparation error 18.75 15.60 10 9637 3995 64485090
Feeling abnormal 18.74 15.60 53 9594 133549 64355536
Drug withdrawal syndrome 18.32 15.60 23 9624 31268 64457817
Palpitations 18.26 15.60 45 9602 104443 64384642
Immunoglobulins decreased 18.19 15.60 7 9640 1311 64487774
Sinus arrest 18.19 15.60 9 9638 3081 64486004
Product dose omission issue 17.18 15.60 66 9581 194681 64294404
Nail growth abnormal 16.59 15.60 5 9642 447 64488638
Pressure of speech 16.30 15.60 6 9641 995 64488090

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H03AA02 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
THYROID THERAPY
THYROID PREPARATIONS
Thyroid hormones
ATC H03AA03 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
THYROID THERAPY
THYROID PREPARATIONS
Thyroid hormones
FDA CS M0021977 Triiodothyronine
FDA EPC N0000175946 l-Triiodothyronine
CHEBI has role CHEBI:60311 thyroid hormones
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Goiter indication 3716002 DOID:12176
Myxedema coma indication 21263006
Hypothyroidism indication 40930008 DOID:1459
Myxedema indication 43153006 DOID:11634
Congenital hypothyroidism indication 190268003 DOID:0050328
Simple goiter indication 267369002
Malignant tumor of thyroid gland indication 363478007 DOID:1781
T3 Suppression for Thyroid Function Test indication
Mild Hypothyroidism indication
Diagnostic Test for Thyroid Dysfunction indication
Myocardial infarction contraindication 22298006 DOID:5844
Thyrotoxic crisis contraindication 29028009 DOID:12837
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Osteoporosis contraindication 64859006 DOID:11476
Diabetes mellitus contraindication 73211009 DOID:9351
Hypopituitarism contraindication 74728003 DOID:9406
Angina pectoris contraindication 194828000
Osteopenia contraindication 312894000
Primary adrenocortical insufficiency contraindication 373662000
Disorder of coronary artery contraindication 414024009




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Hypothyroidism Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Cytobin Tablets Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.08 acidic
pKa2 8.12 acidic
pKa3 8.77 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Thyroid hormone receptor alpha Nuclear hormone receptor AGONIST Kd 10.24 CHEMBL CHEMBL
Thyroid hormone receptor beta Nuclear hormone receptor AGONIST Ki 10.10 CHEMBL CHEMBL
Adenosine receptor A1 GPCR Ki 6.62 DRUG MATRIX
Cytochrome P450 2C9 Enzyme EC50 6.30 WOMBAT-PK
Prothrombin Enzyme EC50 8.92 CHEMBL
Peroxisome proliferator-activated receptor gamma Nuclear hormone receptor Kd 6.15 CHEMBL
Proliferating cell nuclear antigen Nuclear other IC50 5.44 CHEMBL
THAP domain-containing protein 1 Unclassified EC50 9 WOMBAT-PK
GABA-A receptor; anion channel Ion channel IC50 4.64 CHEMBL
Thyroid hormone receptor beta Transcription factor IC50 8.74 CHEMBL
GABA-A receptor; anion channel Ion channel EC50 5.15 CHEMBL

External reference:

IDSource
4022167 VUID
N0000020173 NUI
D01011 KEGG_DRUG
55-06-1 SECONDARY_CAS_RN
4018002 VANDF
4022167 VANDF
C0041014 UMLSCUI
CHEBI:18258 CHEBI
T3 PDB_CHEM_ID
CHEMBL1544 ChEMBL_ID
CHEMBL1201119 ChEMBL_ID
D014284 MESH_DESCRIPTOR_UI
DB00279 DRUGBANK_ID
2634 IUPHAR_LIGAND_ID
653 INN_ID
06LU7C9H1V UNII
5920 PUBCHEM_CID
10814 RXNORM
1964 MMSL
4982 MMSL
d00658 MMSL
002133 NDDF
004882 NDDF
126204001 SNOMEDCT_US
350358003 SNOMEDCT_US
61275002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-2178 TABLET 25 ug ORAL ANDA 26 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-2179 TABLET 5 ug ORAL ANDA 26 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-2180 TABLET 50 ug ORAL ANDA 26 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 16590-303 TABLET 50 1 ORAL ANDA 13 sections
Liothyronine sodium HUMAN PRESCRIPTION DRUG LABEL 1 16714-166 TABLET 5 ug ORAL ANDA 24 sections
Liothyronine sodium HUMAN PRESCRIPTION DRUG LABEL 1 16714-167 TABLET 25 ug ORAL ANDA 24 sections
Liothyronine sodium HUMAN PRESCRIPTION DRUG LABEL 1 16714-168 TABLET 50 ug ORAL ANDA 24 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 33261-964 TABLET 5 ug ORAL ANDA 25 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 39822-0151 INJECTION, SOLUTION 10 ug INTRAVENOUS ANDA 25 sections
Triostat HUMAN PRESCRIPTION DRUG LABEL 1 42023-120 INJECTION 10 ug INTRAVENOUS NDA 25 sections
NP Thyroid 15 HUMAN PRESCRIPTION DRUG LABEL 2 42192-327 TABLET 2.25 ug ORAL unapproved drug other 23 sections
NP Thyroid 120 HUMAN PRESCRIPTION DRUG LABEL 2 42192-328 TABLET 18 ug ORAL unapproved drug other 22 sections
NP Thyroid 30 HUMAN PRESCRIPTION DRUG LABEL 2 42192-329 TABLET 4.50 ug ORAL unapproved drug other 22 sections
NP Thyroid 60 HUMAN PRESCRIPTION DRUG LABEL 2 42192-330 TABLET 9 ug ORAL unapproved drug other 22 sections
NP Thyroid 90 HUMAN PRESCRIPTION DRUG LABEL 2 42192-331 TABLET 13.50 ug ORAL unapproved drug other 22 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42291-417 TABLET 5 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42291-418 TABLET 25 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42291-419 TABLET 50 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42794-018 TABLET 5 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42794-019 TABLET 25 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42794-020 TABLET 50 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43063-884 TABLET 25 ug ORAL ANDA 27 sections
NP Thyroid 60 HUMAN PRESCRIPTION DRUG LABEL 2 45865-566 TABLET 9 ug ORAL unapproved drug other 22 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 50090-3131 TABLET 5 ug ORAL ANDA 27 sections
NP Thyroid 30 HUMAN PRESCRIPTION DRUG LABEL 2 50090-4376 TABLET 4.50 ug ORAL unapproved drug other 22 sections
NP Thyroid 60 HUMAN PRESCRIPTION DRUG LABEL 2 50090-5216 TABLET 9 ug ORAL unapproved drug other 22 sections
NP Thyroid 90 HUMAN PRESCRIPTION DRUG LABEL 2 50090-5229 TABLET 13.50 ug ORAL unapproved drug other 22 sections
Liothyronine sodium HUMAN PRESCRIPTION DRUG LABEL 1 50090-5586 TABLET 5 ug ORAL ANDA 24 sections
Liothyronine sodium HUMAN PRESCRIPTION DRUG LABEL 1 50090-5586 TABLET 5 ug ORAL ANDA 24 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 51407-384 TABLET 5 ug ORAL ANDA 27 sections